The antileishmanial activity of novel oxygenated chalcones and their mechanism of action.
Our previous studies have shown that licochalcone A, an oxygenated chalcone, has antileishmanial and antimalarial activities, and alters the ultrastructure and function of the mitochondria of Leishmania spp. parasites. The present study was designed to investigate the antileishmanial activity and the mechanism of action of a group of new oxygenated chalcones. The tested oxygenated chalcones inhibited the in-vitro growth of Leishmania major promastigotes and Leishmania donovani amastigotes. Treatment of hamsters infected with L. donovani with intraperitoneal administration of two oxygenated chalcones resulted in a significant reduction of parasite load in the liver and the spleen compared with untreated control animals. The oxygenated chalcones also inhibited the respiration of the parasite and the activity of mitochondrial dehydrogenases. Electron microscopic studies illustrated that they altered the ultrastructure of the mitochondria of L. major promastigote. The data clearly indicate that this group of oxygenated chalcones has a strong antileishmanial activity and might be developed into a new antileishmanial drug. The antileishmanial activity of oxygenated chalcones might be the result of interference with function of the parasite mitochondria.
Department of Clinical Microbiology, University Hospital, Rigshospitalet, Copenhagen, Denmark.
L
L
Zhai
M
M
Chen
J
J
Blom
T G
TG
Theander
S B
SB
Christensen
A
A
Kharazmi
D000818:Animals; D000981:Antiprotozoal Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D002599:Chalcone / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D006224:Cricetinae; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007893:Leishmania donovani / Q000187:drug effects* / Q000254:growth & development / Q000648:ultrastructure; D018320:Leishmania major / Q000187:drug effects* / Q000254:growth & development / Q000648:ultrastructure; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy; D007898:Leishmaniasis, Visceral / Q000188:drug therapy; D008264:Macrophages / Q000187:drug effects / Q000469:parasitology; D008297:Male; D008647:Mesocricetus; D008928:Mitochondria / Q000187:drug effects* / Q000201:enzymology / Q000648:ultrastructure; D010088:Oxidoreductases / Q000187:drug effects / Q000378:metabolism; D012119:Respiration / Q000187:drug effects
D000981:Antiprotozoal Agents; D002599:Chalcone; D010088:Oxidoreductases